What Voronoi does

Voronoi is a precision medicine biotechnology company founded in 2015 and headquartered in Songdo, Incheon, South Korea, that develops novel kinase inhibitors and target protein degraders for oncology and autoimmune diseases. The company's core technology is VORONOMICS, a proprietary AI-augmented drug design platform that integrates in-house wet-lab kinase profiling data (~550,000 assay data points per year) with machine learning feedback loops and an in vivo animal testing center to identify and optimize candidates with high selectivity and blood-brain barrier penetration, compressing candidate identification timelines to 1–1.5 years versus an industry-standard ~3 years. Voronoi maintains an 11-program pipeline spanning EGFR-mutant NSCLC (VRN11), HER2-positive solid tumors (VRN10), EGFR/HER2 exon 20 insertions (VRN07, partnered with ORIC), synthetic-lethality targets (VRN16/PKMYT1, VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and an inhaled PAH therapy (VRN13). As of its 2022 securities filing, the company held 174 patents (186 total IP assets), ranking first in Korea and ninth globally in small molecule drug patents.

Name

Voronoi

Legal name

Voronoi, Inc.

Website

https://voronoi.io

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

Voronoi is a Korean clinical-stage biotech using its AI-augmented VORONOMICS platform to develop precision kinase inhibitors for oncology and autoimmune diseases, commercializing through global out-licensing deals.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

akta.pro secondary industries

Antibody-Drug Conjugates (ADCs) & Antibody Conjugates (HLAAAAAE), Translational & Pharmacodynamic Biomarkers (MOA, target engagement, PD/PK-linked markers) (HLAAAMAD), Pulmonary Hypertension & Rare Pulmonary Disease Therapies (HLAIAIAG)

Keywords

• Kinase inhibitor discovery
• Precision oncology therapeutics
• Targeted cancer therapy
• Pharmaceutical out-licensing
• AI drug discovery platform

Headquarters

HQ city

Incheon

HQ country

South Korea

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Technology Licensing / License-Out Deals: Voronoi's primary revenue model is out-licensing its proprietary drug candidates to global pharmaceutical and biotech companies. The company discovers and develops pipeline candidates through Phase 1 clinical stage, then executes license-out agreements that generate upfront payments, milestone payments, and ongoing royalties. Reference deals include: ORIC Pharmaceuticals (EGFR/HER2 exon20, ~$621M total), Bridgepoint (DYRK1A autoimmune, ~$323.5M total), Pyramid Biosciences (MPS1, ~$846M total), and Anvia Therapeutics (VRN04 RIPK1, equity + milestone payments). Cumulative technology export value exceeds KRW 3 trillion.
2. Government Research Grants: Voronoi receives non-dilutive funding from Korea's National New Drug Development Project (KDDF) for preclinical and candidate discovery stages. Multiple pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for government support.
3. Equity Capital / Public Market: Voronoi is listed on KOSDAQ (ticker: 310210). The company raises dilutive capital through public offerings, rights offerings, and convertible bond issuances to fund clinical development. IPO was completed in June 2022. Subsequent capital raises include a KRW 450 billion rights offering in 2023.

Go-to-market motion2 records

Distribution channels5 records

Marketing channels4 records

Core offering

Voronoi discovers and develops targeted kinase inhibitors and related small molecule therapeutics for oncology (EGFR-mutant NSCLC, HER2-positive solid tumors, CCNE1-amplified cancers, BRCA1/2-mutant cancers) and autoimmune/Pulmonary arterial hypertension indications using its proprietary VORONOMICS AI-augmented drug design platform. Its portfolio includes VRN11 (4th-generation EGFR inhibitor), VRN10 (HER2-selective inhibitor), VRN07 (EGFR/HER2 exon20 inhibitor partnered with ORIC), VRN16 (PKMYT1 inhibitor), VRN19 (USP1 inhibitor), VRN13 (inhaled PDGFR inhibitor for PAH), and VRN04 (RIPK1 inhibitor transferred to Anvia Therapeutics). Revenue is generated primarily through out-licensing these pipeline assets to global pharmaceutical partners in exchange for upfront, milestone, and royalty payments.

Product overview

Voronoi is a precision medicine company developing novel targeted kinase inhibitors for oncology and autoimmune diseases. Its core proprietary platform, VORONOMICS, integrates wet-lab data (550,000+ compound assays per year) with AI to accelerate drug discovery, achieving candidate development timelines of 1–1.5 years. The company maintains a pipeline of eight programs spanning lung cancer (VRN11, a 4th-gen EGFR inhibitor), breast and solid tumors (VRN10, a HER2-selective inhibitor), partnered EGFR/HER2 exon 20 assets (VRN07 with ORIC Pharmaceuticals), gynecologic cancers (VRN16/PKMYT1 and VRN19/USP1), an autoimmune therapy (VRN04/RIPK1, transferred to Anvia), and pulmonary hypertension (VRN13, inhaled PDGFR inhibitor). The portfolio emphasizes two key differentiators: exquisite kinase selectivity and high blood-brain barrier penetration.

Differentiator

Problem solved

Functional benefit

Products and services

• VORONOMICS Platform Proprietary drug discovery platform that combines wet-lab data (~550,000 compound assays annually) with AI/ML modeling to rapidly identify and optimize drug candidates engineered for exquisite kinase selectivity and superior blood-brain barrier penetration. Used by Voronoi to generate its internal pipeline of kinase inhibitors.
• VRN11 (REACH-EGFR) Fourth-generation, orally bioavailable EGFR-selective tyrosine kinase inhibitor targeting common (Del19, L858R), uncommon (G719X, L861Q, S768I), and resistance (C797S) EGFR mutations in non-small cell lung cancer. Demonstrates superior blood-brain barrier penetration (Kp,uu,CSF of 2.0 vs ~0.2 for osimertinib) and favorable safety (no DLTs up to 480mg). Phase 1a DCR of 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients.
• VRN10 (LUMIN-HER2) Orally bioavailable, highly selective covalent HER2 tyrosine kinase inhibitor for HER2-positive solid tumors including breast cancer. Active across HER2 mutation subtypes and HER2 amplification, with synergy with HER2 ADCs (trastuzumab deruxtecan/Enhertu) and activity in T-DXd-resistant tumors. Phase 1a HER2 mutation cohort ORR 43% (3/7), DCR 86% (6/7).
• VRN07 (ORIC-114) EGFR/HER2 exon 20 insertion inhibitor for EGFR and HER2 exon 20 mutation-driven solid tumors, partnered with ORIC Pharmaceuticals (Nasdaq-listed) under an October 2020 license agreement with USD 621M total deal value. Demonstrates high brain penetration.
• VRN16 Novel selective orally available PKMYT1 inhibitor leveraging synthetic lethality mechanism, targeting CCNE1-amplified cancers including ovarian, uterine, gastric, and breast cancers. CCNE1 amplification occurs in approximately 8% of solid tumors. Preclinical data demonstrate differentiated selectivity, tolerability, and anti-tumor activity.
• VRN19 Best-in-class orally available USP1 inhibitor targeting BRCA1/2-mutated cancers (ovarian, breast) via synthetic lethality. Demonstrates superior tolerability and potent anti-tumor activity with a broad therapeutic window compared to competing USP1 inhibitors.
• VRN04 Orally available RIPK1 inhibitor targeting TNF-alpha receptor signaling for chronic inflammatory and autoimmune diseases. Transferred to Anvia Therapeutics via asset purchase agreement (competing with programs from Eli Lilly and Sanofi). Voronoi received equity and milestone-based consideration.
• VRN13 Best-in-class inhaled PDGFR inhibitor for pulmonary arterial hypertension (PAH). Localized pulmonary delivery reduces systemic exposure and avoids neurological adverse events associated with oral PDGFR inhibitors such as imatinib.

Quantifiable outcome

• VRN11 Phase 1a: DCR 96.8% (30/31) in heavily pretreated EGFR-mutant NSCLC patients (2+ prior lines)
• +7 more outcomes

Named customers1 record

Segments4 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Seven partnerships are on record, tiered minor and core.

• Australian Government (via Sparked FHIR Standards Accelerator Program)minorOthers · 3 February 2026Voronoi conducted an independent 18-month review of Australia's Sparked FHIR Standards Accelerator Program as a digital health consultancy, finding it 'highly effective' and recommending the development of a national FHIR Standards Roadmap. This represents a non-core consulting engagement for Voronoi as a digital health consultancy.
• Anvia TherapeuticscoreOEM/ Whitelabel/ Licensing Partner · 26 August 2024Voronoi entered into an option agreement with Anvia Therapeutics (US biotech founded by Deerfield) for VRN04, a RIPK1 inhibitor for chronic inflammation and autoimmune diseases. Voronoi received 2.5M shares of Anvia common stock as option fee, with additional equity and cash to be received upon option exercise. Final purchase agreement was signed September 2025, with Voronoi receiving an additional 3M Anvia shares as upfront payment. VRN04 targets TNF-alpha receptor signaling for anti-inflammatory effects, competing with programs from Eli Lilly and Sanofi.
• Korean Ministry of Food and Drug Safety (MFDS)minorOthers · 4 July 2023Voronoi's clinical programs (VRN11, VRN10) have received IND approvals from the Korean Ministry of Food and Drug Safety (MFDS/Korean FDA), enabling clinical trials in Korean patients. The MFDS regulatory pathway complements approvals from Australian TGA, Taiwan FDA, and US FDA.
• Pyramid BiosciencescoreOEM/ Whitelabel/ Licensing Partner · 17 November 2021Voronoi out-licensed MPS1 target solid tumor treatment candidate (VRN08) to Pyramid Biosciences (Boston-based, US) for total deal value of up to $846M (~KRW 1 trillion). Pyramid, founded by executives from Pfizer, Boehringer Ingelheim, Roche, BMS, planned to develop VRN08 for breast cancer and other solid tumors, leveraging a strong oncology advisory board from Harvard, Stanford, and MGH. The program was also supported by Korea's National New Drug Development Project (KDDF).
• Bridgepoint (Brigek Pharmaceuticals)coreOEM/ Whitelabel/ Licensing Partner · 1 August 2021Voronoi out-licensed DYRK1A target autoimmune and neuroinflammatory disease program to Bridgepoint (Nasdaq-listed, US, founded by executives from Eli Lilly, Novartis, Allergan) for upfront of $5M and total deal value of up to $323.5M (~KRW 380 billion). Bridgepoint planned to develop the candidate for psoriasis, ulcerative colitis, Crohn's disease, and neuroinflammation, with Phase 1 planned for 2022.
• Korea National Enterprise for Chimera (KDDF/National New Drug Development Project)coreStrategic or Co-development Partner · 1 January 2021Multiple Voronoi pipeline programs (VRN04, VRN08, VRN10, VRN11, VRN13) have been selected for the Korean government's National New Drug Development Project (KDDF). The KDDF provides preclinical research funding and development support, validating the scientific merit of Voronoi's programs. Preclinical support amounts for VRN11 included ~KRW 1.2 billion over 2 years.
• ORIC Pharmaceuticals (NASDAQ: ORIC)coreOEM/ Whitelabel/ Licensing Partner · 20 October 2020Voronoi out-licensed EGFR/HER2 exon20 insertion mutation NSCLC and solid tumor treatment candidate to ORIC Pharmaceuticals (Nasdaq-listed, US) for upfront payment of $13M and total deal value of up to $621M (~KRW 720 billion). ORIC acquired global rights (excluding Greater China) and initiated Phase 1/2 clinical trials in H2 2021. Voronoi retains ~10% royalty on net sales upon commercialization. This deal served as the first major validation of Voronoi's technology platform and its first unicorn-tier technology export.

Scale indicators10 records

Recent moves10 records

Expansion highlights5 records

Direct peers

• Revolution Medicines: Clinical-stage precision oncology company developing targeted therapies against difficult oncology targets including RAS(ON) inhibitors. Direct comparability with Voronoi on kinase/inhibitor design philosophy, targeted oncology focus, and US-listed biotech business model.
• Nuvalent: Clinical-stage biotech developing precisely designed kinase inhibitors for cancer, with explicit emphasis on selectivity, brain penetration, and overcoming resistance mutations. Closest direct analog to Voronoi's VRN11/VRN10 design philosophy.
• ORIC Pharmaceuticals: Nasdaq-listed precision oncology company that licensed EGFR/HER2 exon20 assets (VRN07) from Voronoi. Both companies focus on resistance-overcoming oncology kinase inhibitors, with ORIC serving as both a licensee partner and a structurally similar US-listed biotech.
• Kura Oncology: Clinical-stage precision oncology company developing small molecule kinase inhibitors targeting cancer drivers and resistance mutations. Comparable business model (targeted kinase inhibitors for oncology) and stage (Phase 1/2 assets).
• Cullinan Oncology: Clinical-stage oncology company developing a diversified pipeline of targeted therapies including kinase inhibitors. Comparable in stage, business model, and precision oncology focus to Voronoi.
• Recursion Pharmaceuticals: AI-driven drug discovery company using high-throughput biology and machine learning to identify novel therapeutics. Comparable to Voronoi's VORONOMICS platform in combining wet-lab data with AI for accelerated drug design.
• Exscientia: AI-driven pharmatech company that designs and develops precision medicines using its AI platform. Comparable to Voronoi's VORONOMICS in AI-augmented drug design, with similar focus on speed and selectivity.
• BridgeBio Pharma: Clinical-stage biotech developing targeted therapies for genetic diseases and cancers, with a multi-asset pipeline and licensing/partnership business model. Comparable to Voronoi in pipeline breadth and partnership-driven commercialization approach.
• Mirati Therapeutics: Precision oncology company (acquired by Bristol Myers Squibb in 2024) that developed targeted kinase inhibitors including KRAS G12C inhibitor Krazati. Direct comparability with Voronoi on precision oncology kinase inhibitor focus and US-listed biotech profile.

Regional players

• Hanmi Pharmaceutical: Korean pharmaceutical company developing innovative oncology and specialty therapeutics. Comparable regional Korean biotech/pharma peer to Voronoi, though operating at larger scale and with more mature commercial products.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/voronoi-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles17 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Voronoi